Law360, New York (October 10, 2012, 2:14 PM ET) -- In the wake of the U.S. Physician Payments Sunshine Act (signed into law in March 2010), European, Asian and Australian governmental bodies and trade associations have been rapidly adopting “Sunshine-like” transparency and disclosure requirements applicable to life sciences companies.
These new requirements vary in scope, rigor and reporting deadlines — creating a patchwork of international requirements — and present significant compliance challenges for life sciences companies that conduct ex-U.S. activities such as clinical trials and international advisory boards, among others.
For instance, in December 2011, France...
Sunshine Overseas: Transparency Rules For Life Sciences
To view the full article, take a free trial now.
